Revenue grew 20.24% to ¥7.83 billion and net profit surged 277.56% to ¥1.29 billion, driven by strong respiratory and cardiovascular product sales. Operating cash flow and R&D investment both increased significantly, and the company paid out a cash dividend exceeding annual net profit.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.